Clinical Trial Update: Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT [NA]

View source ↗

Summary

This trial assessed whether rituximab (Rituxan) can prevent EBV-associated lymphoproliferative disorder after T-cell-depleted unrelated or HLA-mismatched relate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease
• Leukemia
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin's Disease, Leukemia | NA | Status: COMPLETED | Results posted: 2016-02-01